
Inogen (INGN) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
82.3M
Gross Profit
36.4M
44.21%
Operating Income
-7.7M
-9.30%
Net Income
-6.2M
-7.50%
EPS (Diluted)
$-0.25
Balance Sheet Metrics
Total Assets
308.4M
Total Liabilities
110.5M
Shareholders Equity
198.0M
Debt to Equity
0.56
Cash Flow Metrics
Operating Cash Flow
-11.2M
Free Cash Flow
-18.8M
Revenue & Profitability Trend
Inogen Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 335.7M | 315.7M | 377.2M | 358.0M | 308.5M |
Cost of Goods Sold | 181.0M | 189.0M | 223.7M | 181.5M | 170.3M |
Gross Profit | 154.7M | 126.7M | 153.5M | 176.5M | 138.2M |
Gross Margin % | 46.1% | 40.1% | 40.7% | 49.3% | 44.8% |
Operating Expenses | |||||
Research & Development | 21.6M | 20.8M | 21.9M | 16.6M | 14.1M |
Selling, General & Administrative | 175.6M | 182.4M | 164.7M | 150.7M | 136.1M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 197.3M | 203.2M | 186.6M | 167.2M | 150.2M |
Operating Income | -42.5M | -76.5M | -33.1M | 9.2M | -12.0M |
Operating Margin % | -12.7% | -24.2% | -8.8% | 2.6% | -3.9% |
Non-Operating Items | |||||
Interest Income | 5.2M | 6.6M | 2.8M | 129.0K | 909.0K |
Interest Expense | - | - | - | - | - |
Other Non-Operating Income | 850.0K | -32.4M | -53.0M | -710.0K | 5.8M |
Pre-tax Income | -36.5M | -102.3M | -83.3M | 8.7M | -5.3M |
Income Tax | -588.0K | 105.0K | 504.0K | 15.0M | 549.0K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 173.1% | 0.0% |
Net Income | -35.9M | -102.4M | -83.8M | -6.3M | -5.8M |
Net Margin % | -10.7% | -32.5% | -22.2% | -1.8% | -1.9% |
Key Metrics | |||||
EBITDA | -21.5M | -25.4M | 42.6M | 30.9M | 6.6M |
EPS (Basic) | $-1.52 | $-4.42 | $-3.67 | $-0.28 | $-0.27 |
EPS (Diluted) | $-1.52 | $-4.42 | $-3.67 | $-0.28 | $-0.27 |
Basic Shares Outstanding | 23654395 | 23176098 | 22852571 | 22490027 | 21980326 |
Diluted Shares Outstanding | 23654395 | 23176098 | 22852571 | 22490027 | 21980326 |
Income Statement Trend
Inogen Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 113.8M | 125.5M | 187.0M | 235.5M | 212.0M |
Short-term Investments | 0 | 3.0M | 0 | 10.0M | 19.3M |
Accounts Receivable | 29.6M | 42.2M | 62.7M | 24.5M | 29.7M |
Inventory | 24.8M | 21.8M | 34.1M | 31.9M | 24.8M |
Other Current Assets | 13.1M | 13.8M | 19.2M | 26.0M | 17.9M |
Total Current Assets | 185.5M | 207.1M | 304.6M | 329.2M | 305.7M |
Non-Current Assets | |||||
Property, Plant & Equipment | 107.4M | 118.5M | 116.8M | 96.0M | 66.1M |
Goodwill | 49.4M | 54.7M | 65.9M | 126.1M | 135.1M |
Intangible Assets | 30.5M | 34.6M | 177.0K | 60.1M | 68.8M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 8.1M | 3.8M | 2.4M | 3.4M | 17.1M |
Total Non-Current Assets | 110.7M | 119.1M | 100.4M | 160.3M | 156.2M |
Total Assets | 296.2M | 326.2M | 405.0M | 489.5M | 461.9M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 16.6M | 13.5M | 18.2M | 10.3M | 12.5M |
Short-term Debt | 2.8M | 3.7M | 3.5M | 3.4M | 1.9M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 13.0M | 10.0M | - | - | - |
Total Current Liabilities | 76.7M | 72.5M | 65.3M | 61.5M | 56.7M |
Non-Current Liabilities | |||||
Long-term Debt | 16.6M | 18.3M | 19.8M | 23.3M | 8.1M |
Deferred Tax Liabilities | 6.9M | 8.5M | 0 | 0 | 25.0K |
Other Non-Current Liabilities | - | - | - | 15.4M | 26.9M |
Total Non-Current Liabilities | 45.6M | 48.9M | 42.3M | 57.8M | 55.5M |
Total Liabilities | 122.3M | 121.4M | 107.6M | 119.3M | 112.2M |
Equity | |||||
Common Stock | 24.0K | 23.0K | 23.0K | 23.0K | 22.0K |
Retained Earnings | -152.8M | -116.9M | -14.5M | 69.3M | 75.6M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 173.9M | 204.8M | 297.4M | 370.2M | 349.6M |
Key Metrics | |||||
Total Debt | 19.4M | 21.9M | 23.3M | 26.7M | 10.0M |
Working Capital | 108.8M | 134.6M | 239.3M | 267.7M | 249.0M |
Balance Sheet Composition
Inogen Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -35.9M | -102.4M | -83.8M | -6.3M | -5.8M |
Depreciation & Amortization | 21.0M | 18.2M | 23.5M | 21.6M | 18.6M |
Stock-Based Compensation | 7.4M | 7.4M | 12.3M | 10.9M | 8.2M |
Working Capital Changes | -13.1M | 9.2M | -45.3M | -21.1M | -1.3M |
Operating Cash Flow | -18.3M | -59.1M | -108.7M | 8.0M | 20.7M |
Investing Activities | |||||
Capital Expenditures | -15.0M | -26.5M | -21.2M | -23.9M | -17.3M |
Acquisitions | 0 | -29.6M | 0 | 0 | 0 |
Investment Purchases | -32.7M | -26.9M | 0 | -10.0M | -22.8M |
Investment Sales | 35.5M | 24.0M | 10.0M | 19.3M | 14.5M |
Investing Cash Flow | -11.9M | -58.8M | -10.9M | -14.5M | -25.4M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | -546.0K | -518.0K | -1.4M | -647.0K | -350.0K |
Free Cash Flow | -11.2M | -30.2M | -58.8M | -434.0K | 19.4M |
Net Change in Cash | -30.8M | -118.4M | -120.9M | -7.1M | -5.1M |
Cash Flow Trend
Inogen Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-5.69
Forward P/E
-5.58
Price to Book
1.17
Price to Sales
0.68
PEG Ratio
0.15
Profitability Ratios
Profit Margin
-7.58%
Operating Margin
-6.64%
Return on Equity
-13.46%
Return on Assets
-6.24%
Financial Health
Current Ratio
3.03
Debt to Equity
9.54
Beta
1.81
Per Share Data
EPS (TTM)
$-1.06
Book Value per Share
$7.38
Revenue per Share
$13.78
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
ingn | 235.3M | -5.69 | 1.17 | -13.46% | -7.58% | 9.54 |
Abbott Laboratories | 234.4B | 16.89 | 4.63 | 30.93% | 32.43% | 26.50 |
Boston Scientific | 144.2B | 57.93 | 6.43 | 11.55% | 13.55% | 53.09 |
Monogram | 248.7M | -13.28 | 25.56 | -228.82% | 0.00% | 3.44 |
TriSalus Life | 232.9M | 0.09 | -7.83 | 128.34% | -86.61% | -1.73 |
CVRx | 227.8M | -3.29 | 3.93 | -92.33% | -95.61% | 87.24 |
Financial data is updated regularly. All figures are in the company's reporting currency.